A Phase 2a, Randomized, Double-blind, Placebo-controlled Study To Evaluate Safety And Efficacy Of Pf-06700841 In Subjects With Moderate To Severe Plaque Psoriasis
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs PF 6700841 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Pfizer
- 08 Mar 2017 Planned End Date changed from 1 May 2018 to 30 May 2018.
- 08 Mar 2017 Planned primary completion date changed from 1 May 2018 to 30 May 2018.
- 10 Jan 2017 Status changed from not yet recruiting to recruiting.